SCHEMBL25373726

SCHEMBL25373726

Nc1cc2c(Nc3ccnc(-c4ccccc4F)c3)ncnc2cc1N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 11/20 0.48
▸ MAPT P10636 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ AHR P35869 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ STK4 Q13043 1/20 0.41
▸ STK3 Q13188 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41
▸ TTBK1 Q5TCY1 1/20 0.40
▸ TTBK2 Q6IQ55 1/20 0.40
▸ MAP4K4 O95819 2/20 0.39
▸ ERBB2 P04626 2/20 0.39
▸ ERBB4 Q15303 2/20 0.39
▸ CIT O14578 1/20 0.39
▸ GAK O14976 1/20 0.39
▸ EPHB6 O15197 1/20 0.39
▸ ABCC4 O15439 1/20 0.39
▸ DAPK3 O43293 1/20 0.39
▸ RIPK2 O43353 1/20 0.39
▸ NR1I2 O75469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25662634 0.88 EGFR (0.49) EGFRMAPTMAPK1AHRHTT
SCHEMBL25249103 0.86 EGFR (0.45) EGFRMAPTHTTCYP1A2
SCHEMBL26058048 0.84 EGFR (0.43) EGFRMAPTMAPK1AHRHTT
SCHEMBL25373220 0.83 EGFR (0.47) EGFRAHRMAP4K4METKDR
SCHEMBL25216766 0.82 EGFR (0.56) EGFRLRRK2ERBB2ERBB4CIT
SCHEMBL29382670 0.82 EGFR (0.46) EGFRLRRK2ERBB2ERBB4CIT
SCHEMBL25211108 0.82 EGFR (0.46) EGFRLRRK2ERBB2ERBB4CIT
SCHEMBL29383085 0.78 EGFR (0.60) EGFRAHRERBB2METKDR
SCHEMBL8870722 0.78 EGFR (0.57) EGFRMAPK1HTTTTBK1TTBK2
SCHEMBL25213722 0.77 EGFR (0.51) EGFRLRRK2ERBB2ERBB4CIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 — — US disclosed
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 — — US disclosed
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-08-31 — — US disclosed
EP-4194443-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-06-14 — — EP disclosed
EP-4194443-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-06-14 — — EP disclosed
WO-2022033410-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海和誉生物医药科技有限公司 2022-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271936-A1 EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF EGFR, WEE1, WEE2 EGFR 1/4885MAPT 4096/4885MAPK1 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback